Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post-hoc analysis from the randomized controlled PRE-D trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Clemmensen, Kim K B ; Blond, Martin Bæk ; Amadid, Hanan ; Bruhn, Lea ; Vistisen, Dorte ; Karstoft, Kristian ; Persson, Frederik ; Ried-Larsen, Mathias ; Holst, Jens J ; Wewer Albrechtsen, Nicolai J ; Torekov, Signe S ; Quist, Jonas S ; Jørgensen, Marit E ; Faerch, Kristine. / No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes : A post-hoc analysis from the randomized controlled PRE-D trial. I: Diabetes, Obesity and Metabolism. 2021 ; Bind 23, Nr. 2. s. 530-539.

Bibtex

@article{a201d01bf1a94a3793678b3929a3ffe2,
title = "No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post-hoc analysis from the randomized controlled PRE-D trial",
abstract = "AIM: To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.MATERIALS AND METHODS: One-hundred and twenty individuals with overweight (body mass index ≥ 25 kg/m 2 ) and prediabetes (HbA1c of 39-47 mmol/mol) were randomized to a 13-week intervention with dapagliflozin (10 mg once daily), metformin (850 mg twice daily), exercise (30 minutes of interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up). Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT. RESULTS: At baseline, the median (Q1; Q3) age was 62 (54; 68) years, median fasting plasma glucagon concentration was 11 (7; 15) pmol/L, mean (SD) HbA1c was 40.9 (2.3) mmol/mol and 56% were women. Compared with the control group, fasting glucagon did not change in any of the groups from baseline to the end of the intervention (dapagliflozin group: -5% [95% CI: -29; 26]; exercise group: -8% [95% CI: -31; 24]; metformin group: -2% [95% CI: -27; 30]). Likewise, there were no differences in insulin/glucagon ratio and glucagon suppression during the OGTT between the groups.CONCLUSIONS: In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.",
keywords = "exercise, glucagon, metformin, obesity, prediabetes, sodium-glucose co-transporter-2 inhibitor, exercise, glucagon, metformin, obesity, prediabetes, sodium-glucose co-transporter-2 inhibitor",
author = "Clemmensen, {Kim K B} and Blond, {Martin B{\ae}k} and Hanan Amadid and Lea Bruhn and Dorte Vistisen and Kristian Karstoft and Frederik Persson and Mathias Ried-Larsen and Holst, {Jens J} and {Wewer Albrechtsen}, {Nicolai J} and Torekov, {Signe S} and Quist, {Jonas S} and J{\o}rgensen, {Marit E} and Kristine Faerch",
note = "This article is protected by copyright. All rights reserved.",
year = "2021",
month = feb,
doi = "10.1111/dom.14246",
language = "English",
volume = "23",
pages = "530--539",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes

T2 - A post-hoc analysis from the randomized controlled PRE-D trial

AU - Clemmensen, Kim K B

AU - Blond, Martin Bæk

AU - Amadid, Hanan

AU - Bruhn, Lea

AU - Vistisen, Dorte

AU - Karstoft, Kristian

AU - Persson, Frederik

AU - Ried-Larsen, Mathias

AU - Holst, Jens J

AU - Wewer Albrechtsen, Nicolai J

AU - Torekov, Signe S

AU - Quist, Jonas S

AU - Jørgensen, Marit E

AU - Faerch, Kristine

N1 - This article is protected by copyright. All rights reserved.

PY - 2021/2

Y1 - 2021/2

N2 - AIM: To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.MATERIALS AND METHODS: One-hundred and twenty individuals with overweight (body mass index ≥ 25 kg/m 2 ) and prediabetes (HbA1c of 39-47 mmol/mol) were randomized to a 13-week intervention with dapagliflozin (10 mg once daily), metformin (850 mg twice daily), exercise (30 minutes of interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up). Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT. RESULTS: At baseline, the median (Q1; Q3) age was 62 (54; 68) years, median fasting plasma glucagon concentration was 11 (7; 15) pmol/L, mean (SD) HbA1c was 40.9 (2.3) mmol/mol and 56% were women. Compared with the control group, fasting glucagon did not change in any of the groups from baseline to the end of the intervention (dapagliflozin group: -5% [95% CI: -29; 26]; exercise group: -8% [95% CI: -31; 24]; metformin group: -2% [95% CI: -27; 30]). Likewise, there were no differences in insulin/glucagon ratio and glucagon suppression during the OGTT between the groups.CONCLUSIONS: In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.

AB - AIM: To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.MATERIALS AND METHODS: One-hundred and twenty individuals with overweight (body mass index ≥ 25 kg/m 2 ) and prediabetes (HbA1c of 39-47 mmol/mol) were randomized to a 13-week intervention with dapagliflozin (10 mg once daily), metformin (850 mg twice daily), exercise (30 minutes of interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up). Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT. RESULTS: At baseline, the median (Q1; Q3) age was 62 (54; 68) years, median fasting plasma glucagon concentration was 11 (7; 15) pmol/L, mean (SD) HbA1c was 40.9 (2.3) mmol/mol and 56% were women. Compared with the control group, fasting glucagon did not change in any of the groups from baseline to the end of the intervention (dapagliflozin group: -5% [95% CI: -29; 26]; exercise group: -8% [95% CI: -31; 24]; metformin group: -2% [95% CI: -27; 30]). Likewise, there were no differences in insulin/glucagon ratio and glucagon suppression during the OGTT between the groups.CONCLUSIONS: In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.

KW - exercise

KW - glucagon

KW - metformin

KW - obesity

KW - prediabetes

KW - sodium-glucose co-transporter-2 inhibitor

KW - exercise, glucagon, metformin, obesity, prediabetes, sodium-glucose co-transporter-2 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85096652496&partnerID=8YFLogxK

U2 - 10.1111/dom.14246

DO - 10.1111/dom.14246

M3 - Journal article

C2 - 33146457

VL - 23

SP - 530

EP - 539

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -

ID: 61210447